| |
Turnkey pharmaceutical manufacturing facilities and a 75% property tax exemption make expanding your bioscience business to Puerto Rico easier than ever. It's not what's next, it's where. Puerto Rico.
|
|
Today’s Big NewsJan 27, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency.
|
|
| By Andrea Park,Nick Paul Taylor According to Evaluate’s forecasts, the biggest potential drug launches of the coming year stand to generate a collective $29 billion in annual sales by the end of the decade, nearly double the estimate for last year’s top 10. |
|
|
|
By Conor Hale The FDA has tapped Sara Brenner to serve as acting commissioner as it awaits new leadership from the Trump administration to complete the congressional confirmation process. |
By Fraiser Kansteiner Activist Investor Starboard Value stopped short of nominating any directors to Pfizer’s board ahead of a Jan. 25 deadline, Bloomberg reported Monday. A Starboard-backed director—or two—would have given the investor more leverage as it attempts to influence Pfizer’s turnaround strategy. |
By Gabrielle Masson Cell therapy biotech Aurion is moving forward with plans to IPO despite a pending lawsuit from one of its existing investors. |
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now.
|
|
By Zoey Becker The company's board of directors unanimously rejected partner Biogen's $469 million buyout proposal, finding that it "significantly undervalues" the company and is not in the best interest of shareholders. |
By Andrea Park Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch with a new commercial leader. |
By Nick Paul Taylor Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic dysfunction-associated steatohepatitis analyses to send its stock up about 100%. |
By Gabrielle Masson The FDA’s guidance detailing diversity action plans for clinical trials that evaluate drugs, devices and other medical products has been taken down from the agency’s website. |
By Angus Liu Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them as new standard treatments for certain colorectal cancer patients. |
By Nick Paul Taylor Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. The repeat offenders received their latest dressing-downs over a gathering of healthcare professionals and problems with the disclosure of transfers of value, respectively. |
By James Waldron Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist. |
By Fraiser Kansteiner Pfizer—which purchased Biohaven for $11.6 billion in 2022—is committing more than $59.7 million to resolve kickback allegations tied to its neuroscience subsidiary's migraine med Nurtec. |
By Conor Hale The author of the seminal cancer biography The Emperor Of All Maladies and the co-founder of LinkedIn are looking to connect their skills to the development of new medicines. |
By Nick Paul Taylor Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and lay off 75% of its employees to hunker down while exploring strategic alternatives. |
By Nick Paul Taylor Havas Health Network has rebranded a U.K. agency. Havas Life Medicom is now Havas Life London, a group focused on brand, corporate and cause-related communications in global health and rare diseases. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of Intra-Cellular Therapies to former First Lady Jill Biden’s appearance at Fierce JPM Week. |
|
|---|
|
|
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now.
|
|
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
